ArticleNeurocritical care2026
Value of Sympathetic Skin Response for Identifying Paroxysmal Sympathetic Hyperactivity in Patients with Prolonged Disorders of Consciousness.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aimed to explore the value of sympathetic skin response (SSR) for identifying paroxysmal sympathetic hyperactivity (PSH) in patients with prolonged disorders of consciousness (PDOC).
methodsThis retrospective observational study included 124 consecutive patients with PDOC from March 2022 to March 2024. On the basis of the PSH Assessment Method (PSH-AM), the patients were classified into the PSH-positive (PSH + , n = 43) and PSH-negative (PSH - , n = 81) groups. Among them, 75 patients (PSH - , n = 44; PSH + , n = 31) with elicitable SSR were included in the final analysis.
resultsThere were no significant differences between groups in the SSR elicitation rate (P = 0.08) or in SSR latency (P > 0.05). By contrast, both SSR amplitude and SSR amplitude difference were significantly elevated in the PSH + group compared with the PSH- group (P < 0.001). In patients with elicitable SSR (n = 75), multivariable logistic regression analysis including age, CRS-R score, right SSR amplitude, left SSR amplitude, and SSR amplitude difference simultaneously (with no significant multicollinearity) demonstrated that only the SSR amplitude difference was independently associated with PSH (OR per 0.1 mV = 2.08; 95% CI: 1.49-3.45, P = 0.004). ROC analysis showed that the SSR amplitude difference had excellent diagnostic accuracy (AUC = 0.96; 95% CI: 0.93-0.998). The sensitivity analysis, including 124 patients (with absent SSR coded as 0 mV), indicated that age (OR = 0.96; 95% CI: 0.92-0.999, P = 0.05), CRS-R score (OR = 0.77; 95% CI: 0.65-0.89, P = 0.001), and SSR amplitude difference (OR per 0.1 mV = 1.47; 95% CI: 1.22-1.86, P < 0.001) were independently associated with PSH. ROC analysis demonstrated that the SSR amplitude difference alone had good diagnostic accuracy (AUC = 0.77; 95% CI: 0.666-0.875), and the combination of age, CRS-R score, and SSR amplitude difference achieved the highest diagnostic accuracy (AUC = 0.888; 95% CI: 0.826-0.951).
conclusionsThe SSR amplitude difference is independently associated with PSH in patients with PDOC and demonstrates high diagnostic accuracy, both alone and in combination with age and CRS-R score. It may serve as a valuable, noninvasive electrophysiological marker to aid in identifying PSH in this patient population.
Indexed as
Identifiers
42547672What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.